Atai Life Sciences shares fall 1.50% after-hours following earnings report.

Atai Life Sciences N.V. declined 1.50% in after-hours trading, following the release of its earnings results. The company, a Germany-based clinical-stage biopharmaceutical company, focuses on developing treatments for various mental health disorders. The earnings report may have disappointed investors, leading to the stock's decline.